ZURA BIO LIMITED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
ZURA BIO LIMITED (ZURA) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $2.36 million as of 2024-06-30, per its 10-Q filed 2024-08-13.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-03-19
- 2024-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $2.36M.
- 2024-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.60M.
- 2023-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $990.00K.
- 2023-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.95M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2024-06-30 | $2.36M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.60M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $990.00K 10-K · filed 2026-03-19 |
| 2023-09-30 | $1.95M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $2.07M 10-Q · filed 2023-11-13 |
| 2023-03-31 | $1.54M 10-Q · filed 2023-11-13 |
| 2022-12-31 | $7.76M 10-K · filed 2024-03-28 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |